These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24681228)

  • 21. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
    Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
    Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anti-HBs persistence after revaccination with three doses of hepatitis B vaccines among non-responsive adults: 24-month of follow-up].
    Zhang L; Lyu J; Yan B; Liu J; Feng Y; Chen S; Zhou L; Liang X; Cui F; Wang F; Xu A
    Zhonghua Yu Fang Yi Xue Za Zhi; 2015 Sep; 49(9):782-7. PubMed ID: 26733135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune response to different types of hepatitis B vaccine booster doses 2-32 years after the primary immunization schedule and its influencing factors.
    Zhao YL; Pan LL; Hao ZY; Jin F; Zhang YH; Li MJ; Zhang XJ; Han BH; Zhou HS; Ma TL; Wang F; Ma JC; Shen LP; Li Q
    Int J Infect Dis; 2020 Apr; 93():62-67. PubMed ID: 32004687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anti-HBs persistence after revaccination with three doses of hepatitis B vaccine among non-responsive adults: a 4-year of follow-up study].
    Zhang L; Yan BY; Lyu JJ; Liu JY; Feng Y; Wu WL; Cao CZ; Chen SY; Zhou LB; Liang XF; Cui FQ; Wang FZ; Zhang GM; Xu AQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jun; 50(6):497-502. PubMed ID: 27256728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of anti-HBs persistence after hepatitis B vaccination on two-dose schedule and three-dose schedule among adults: results from a 12-year follow up study in China.
    Lu J; Yan B; Liu J; Wu W; Feng Y; Xu A; Zhang L
    Hum Vaccin Immunother; 2019; 15(5):1171-1176. PubMed ID: 30499752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules.
    Agladioglu S; Beyazova U; Camurdan AD; Sahin F; Atak A
    Infection; 2010 Aug; 38(4):269-73. PubMed ID: 20512395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
    Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
    Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher rate of long-term serologic response of four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: 4-year follow-up of a randomised controlled trial.
    Chaiwarith R; Praparattanapan J; Kotarathititum W; Wipasa J; Chaiklang K; Supparatpinyo K
    AIDS Res Ther; 2019 Nov; 16(1):33. PubMed ID: 31711528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effect of booster dose vaccination 21- to 32-years after primary vaccination with hepatitis B vaccine in the population born from 1986 to 1996 in Zhengding County of Hebei Province].
    Zhang XJ; Wu ZW; Zhang YH; Li MJ; Zhou HS; Han BH; Hao ZY; Chu J; Gao Z; Ma JC; Zhao YL
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):942-946. PubMed ID: 32907282
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
    Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
    J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B Virus Revaccination With Standard Versus Pre-S Vaccine in Previously Immunized Patients With Celiac Disease.
    Heshin-Bekenstein M; Turner D; Shamir R; Bar-Meir M; Dagan R; Zevit N; Silbermintz A
    J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):400-3. PubMed ID: 25988560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementation of hepatitis B vaccine in high-risk young adults with waning immunity.
    Posuwan N; Vorayingyong A; Jaroonvanichkul V; Wasitthankasem R; Wanlapakorn N; Vongpunsawad S; Poovorawan Y
    PLoS One; 2018; 13(8):e0202637. PubMed ID: 30125298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: A randomized, double-blinded, parallel-controlled trial.
    Shi J; Feng Y; Gao L; Feng D; Yao T; Shi S; Zhang Y; Liang X; Wang S
    Vaccine; 2017 Apr; 35(18):2443-2448. PubMed ID: 28343774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders.
    Das K; Gupta RK; Kumar V; Kar P
    World J Gastroenterol; 2003 May; 9(5):1132-4. PubMed ID: 12717874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effectiveness of rapid hepatitis B vaccination with different vaccine dosages and types in adults].
    Nie L; Pang XH; Zhang Z; Ma JX; Liu XY; Qiu Q; Liang Y; Li Q; Zhang W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Sep; 38(9):1151-1155. PubMed ID: 28910921
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants.
    Vesikari T; Martin JC; Liss CL; Liska V; Schödel FP; Bhuyan PK
    Pediatr Infect Dis J; 2011 Jul; 30(7):e109-13. PubMed ID: 21552183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence of immunity in healthy adults aged ≥ 50 years primed with a hepatitis B vaccine 3 years previously.
    Sharma R; Ahlm C; Ostergaard L; Dowell A; Tran C; Thomas S; Eymin C
    Hum Vaccin Immunother; 2015; 11(7):1709-16. PubMed ID: 25996838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine.
    Zhang W; Han L; Lin C; Wang H; Pang X; Li L; Gao P; Lin H; Gong X; Tang Y; Ma J; Zhang H; Wang C; Yang P; Li H; Sun M; He X
    Vaccine; 2011 Aug; 29(37):6276-82. PubMed ID: 21722684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.
    Vesikari T; Langley JM; Segall N; Ward BJ; Cooper C; Poliquin G; Smith B; Gantt S; McElhaney JE; Dionne M; van Damme P; Leroux-Roels I; Leroux-Roels G; Machluf N; Spaans JN; Yassin-Rajkumar B; Anderson DE; Popovic V; Diaz-Mitoma F;
    Lancet Infect Dis; 2021 Sep; 21(9):1271-1281. PubMed ID: 33989539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults.
    Aguilar-Betancourt A; González-Delgado CA; Cinza-Estévez Z; Martínez-Cabrera J; Véliz-Ríos G; Alemán-Zaldívar R; Alonso-Martínez MI; Lago-Baños M; Puble-Alvarez N; Delahanty-Fernandez A; Juvier-Madrazo AI; Ortega-León D; Olivera-Ruano L; Correa-Fernández A; Abreu-Reyes D; Soto-Mestre E; Pérez-Pérez MV; Figueroa-Baile N; Pérez LH; Rodríguez-Silva A; Martínez-Díaz E; Guillén-Nieto GE; Muzio-González VL
    Hum Vaccin; 2008; 4(1):54-9. PubMed ID: 18441530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.